New hormonal Rx for breast CA approved

Health,Women's Health |

Researchers are cautiously enthusiastic about anastrozole (Arimidex) a new hormonal agent that has shown a 22% increased survival rate for postmenopausal women treated for metastatic breast cancer.  Anastrozole which has just been approved by the Health Protection Branch of Health Canada has the added benefit of being a well-tolerated drug with minimal side effects.  Two identical international trials one in North America and one in Europe and Australia were conducted with more than 500 postmenopausal women unsuccessfully treated with tamoxifen and ready for second-line hormone therapy. Two-hundred and sixty-three women were randomized to receive either 1 mg/day or 10 mg/d anastrozole and 253 were randomized to receive 40 mg megestrol acetate the standard second-line hormonal therapy.   (more…)